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ABSTRACT: Pterin-containing natural products have diverse functions in life, but an eﬃcient and easy scheme for their in vitro
synthesis is not available. Here we report a chemoenzymatic 14-step, one-pot synthesis that can be used to generate 13C- and
15N-labeled dihydrofolates (H2F) from glucose, guanine, and p-aminobenzoyl-L-glutamic acid. This synthesis stands out from
previous approaches to produce H2F in that the average yield of each step is >91% and it requires only a single puriﬁcation
step. The use of a one-pot reaction allowed us to overcome potential problems with individual steps during the synthesis.
The availability of labeled dihydrofolates allowed the measurement of heavy-atom isotope eﬀects for the reaction catalyzed
by the drug target dihydrofolate reductase and established that protonation at N5 of H2F and hydride transfer to C6 occur
in a stepwise mechanism. This chemoenzymatic pterin synthesis can be applied to the eﬃcient production of other folates and a
range of other natural compounds with applications in nutritional, medical, and cell-biological research.
■ INTRODUCTION
Pterin is a common motif found in natural products. Folate,
the essential vitamin that fuels the one-carbon cycle for the
biosynthesis of nucleotide and amino acid building blocks, was
one of the ﬁrst natural products found to contain pterin.1,2
The metabolic importance of pterins is illustrated by their
integration into enzyme cofactors such as molybdopterin and
tetrahydrobiopterin.3−5 Pterin natural products are also used as
pigments in the butterﬂies Catopsilia argante and Appias nero,6
whereas biopterin-α-glucoside serves as a natural sunscreen
that protects cellular contents from photoinduced damage in
photosynthetic cyanobacteria.7
5,6,7,8-Tetrahydrofolic acid (H4F), which in addition to the
pterin ring system contains p-aminobenzoic acid (pABA) and
L-glutamic acid (Glu), is required for the biosynthesis of
metabolites that are key for cell survival and replication.2
A one-carbon unit in diﬀerent oxidation states can be added at
N5 and/or N10 of H4F and used to produce metabolites such as
thymidylate, purines, glycine, serine, and S-adenosylmethionine
(SAM) (Figure 1).8 Because of the central importance of
folate biochemistry for cell replication and survival, dihydrofolate
reductase (DHFR), thymidylate synthase (TS), and serine
hydroxymethyltransferase (SHMT) have long been exploited as
important drug targets in the treatment of bacterial infections,9
malaria,10,11 and cancer,12,13 and the DHFR-targeting drugs
trimethoprim, proguanil, pyrimethamine, and methotrexate are
listed as essential medicines by the World Health Organization
(WHO).14 Nevertheless, as with many clinically used drugs,
resistance to antifolates has begun to emerge,15−17 and investi-
gation of the enzymes of the one-carbon cycle is an important
part of inhibitor design strategies.18
Detailed mechanistic insight into enzyme-catalyzed reactions
is often obtained by isotopic labeling and measurement of kinetic
isotope eﬀects (KIEs)19−22 or spectroscopic analysis.23,24
Information derived from regio- and stereospeciﬁc substrate
labeling has been used to design inhibitors with dissociation
constants in themicro- to picomolar range.25 However, the use of
these techniques to investigate folate-dependent enzymes is
hindered by the absence of a general and eﬃcient method to
speciﬁcally label atoms of the pterin ring system, particularly at
N5, C6, C7, and C9, which are directly linked to the chemistry
of the catalyzed reactions. Folate and its derivatives can be
synthesized by connecting the pterin, pABA, and glutamate
groups in sequential order,26 and several synthetic strategies
to incorporate an isotopic label into pterin in a regiospeciﬁc
manner have been reported.27−30 Pterins have been synthesized
by condensing guanidine or dihydroxyacetone with the respec-
tive heterocyclic starting materials, and N5-, C2-, and C6-labeled
folates have beenmade previously.27,28However, because symmetric
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reagents are used in these syntheses, regioselective isotope
labeling of C7 and C9 cannot easily be achieved.28,30 In all cases,
the yields of labeled folate or derivatives are low (<5% overall
yield), and the procedures depend on multiple puriﬁcation
steps. Chemoenzymatic strategies have also been described,31−33
whereby H4F was condensed with
11C-formaldehyde or
14C-formic acid to yield the corresponding isotopically labeled
[11C]5,10-methylene-H4F, [
14C]5-formyl-H4F, and [
14C]10-form-
yl-H4F. However, a general and eﬃcient method to label the pterin
ring in folates has never been developed.
In nature, the pterin ring in folate is formed from guanosine
triphosphate (GTP) in one biochemical step catalyzed by GTP
cyclohydrolase (GTP-CH),34,35 an enzyme found in all king-
doms of life ranging from archaebacteria, insects, plants to
humans. In all GTP-CH-catalyzed reactions, GTP is converted to
a pterin via a set of tandem reactions that have no equivalent in
organic chemistry. GTP cyclohydrolase I (GTP-CH-I) catalyzes
the formation of 7,8-dihydroneopterin triphosphate (DHNTP)
from GTP by mediating four distinct chemical reactions
(Figure S1): hydrolysis of the purine ring yielding an N-formyl
intermediate, N-deformylation, a stereospeciﬁc Amadori rear-
rangement of the ribose moiety, and ring closure to form
the pterin.36−38 Because no symmetric reagent is used in this
reaction, GTP-CH-I can be used to synthesize the pterin ring
system of folate with heavy isotopes incorporated regio- and
stereoselectively.39 It is therefore surprising that GTP-CH-I has
not been used in any in vitro enzymatic pathway to synthesize
folates. Perhaps the low catalytic turnover (kcat = 0.05 s
−1)40 and
the rather low stability of the product 7,8-dihyropterin41 toward
oxygen and light have limited the use of GTP-CH-I in synthesis.
Here we report a 14-step one-pot chemoenzymatic synthesis of
7,8-dihydrofolic acid (H2F) that exploits the well-established
procedures to isotopically label GTP39,42,43 by using GTP-CH-I to
site-speciﬁcally isotope-label pterins. The low enzymatic activity
and product instability of GTP-CH-I were addressed by enzymatic
coupling. By means of our methodology, H2F enriched with stable
isotopes at N5 and C6 could be synthesized eﬃciently in pure
form in >30% yield from isotopically enriched D-glucose and
guanine. Given the high degree of purity and isotopic enrichment
(>97%; see the Supporting Information), heavy-atom KIEs could
be measured to investigate the mechanism of the Escherichia coli
DHFR (EcDHFR)-catalyzed reduction of H2F to H4F.
■ RESULTS AND DISCUSSION
In Vitro Synthesis of Folate. The biosynthetic pathway to
folate in E. coli uses the building blocks D-glucose, guanine, and
Figure 1. Folate coenzymes in one-carbon metabolism. Folic acid is converted to 7,8-dihydrofolic acid (H2F) and 5,6,7,8-tetrahydrofolic acid (H4F).
One-carbon units attached to H4F are highlighted. Abbreviations: 1, dihydrofolate reductase (DHFR); 2, 10-formyl-H4F synthetase (FTHFS);
3, 10-formyl-H4F dehydrogenase (FDH); 4, 5,10-methenyl-H4F cyclohydrolase (MTHFC); 5, 5,10-methylene-H4F dehydrogenase (MTHFD);
6, 5,10-methylene-H4F reductase (MTHFR); 7, methionine synthase (MS); 8, serine hydroxymethyltransferase (SHMT); 9, thymidylate synthase
(TS); 10, 5,10-methenyl-H4F synthetase (MTHFS); 11, 5-formimino-H4F cyclodeaminase (FTCD); SAM, S-adenosylmethionine.
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p-aminobenzoyl-L-glutamate (pABA-Glu). In the biosynthetic
scheme of H2F (Figure 2), C2, C3, and C4 of glucose correspond
to C7, C6, and C9 of H2F and N1, C2, N3, C4, C5, C6, N7, and
N9 of guanine correspond to N3, C2, N1, C4b, C4a, C4, N5, and
N8 in H2F. GTP is the key intermediate in this synthetic
pathway, connecting the purine salvage pathway to de novo
folate biosynthesis. Accordingly, a minimum of 14 enzymes need
to be assembled in vitro to produce H2F.
The GTP biosynthetic pathway is composed of enzymes from
the pentose phosphate and purine salvage pathways (Figures 2
and S2). D-Glucose serves as the starting material, which is
transformed into phosphoribose pyrophosphate (PRPP) in
ﬁve steps that are catalyzed by hexokinase (HK), glucose
6-phosphate dehydrogenase (G6PDH), 6-phosphogluconate
dehydrogenase (6PGDH), phosphoriboisomerase (PRI), and
ribose-phosphate pyrophosphokinase (phosphoribosylpyro-
phosphate synthetase, PRS).44 PRPP is then combined with
guanine to form GMP under xanthine guanine phosphoribosyl
transferase (XGPRT) catalysis. The resulting GMP is con-
verted to the corresponding nucleotide triphosphate in reactions
catalyzed by guanylate kinase (GK) and pyruvate kinase (PK).
Since HK and GK use ATP as the phosphate source, PK can also
function as the recycling enzyme. On the other hand, PRS uses
ATP as the pyrophosphate source, so myokinase (MK) was
included to regenerate ATP fromAMP.45 A signiﬁcant amount of
NADP+ is also needed for GTP biosynthesis. Hence, the recently
developed glutathione reductase (GR)/glutaredoxin 2 (GRX2)
recycling system was used to regenerate the oxidized cofac-
tor.44 The GR/GRX2 system uses disulﬁdes like 2-hydroxyethyl
Figure 2. Strategy for the synthesis of 7,8-dihydrofolate (H2F).
Guanosine triphosphate (GTP) was made via the pentose phosphate
and purine salvage pathways under hexokinase (HK), glucose
6-phosphate dehydrogenase (G6PDH), 6-phosphogluconate dehydro-
genase (6PGDH), phosphoriboisomerase (PRI), ribose-phosphate
pyrophosphokinase (PRS), xanthine guanine phosphoribosyl trans-
ferase (XGPRT), guanylate kinase (GK), and pyruvate kinase (PK)
catalysis. In the folate de novo pathway, GTP is converted to
7,8-dihydroneopterin (DHN) under catalysis by GTP cyclohydrolase
I (GTP-CH-I), 7,8-dihydroneopterin pyrophosphatase (DHNTPase),
and alkaline phosphatase (ALP); DHN is then converted to H2F under
catalysis by dihydroneopterin aldolase (DHNA), 6-hydroxymethyl
7,8-dihydropterin pyrophosphokinase (HPPK), and dihydropteroate
synthase (DHPS). The additional enzymes myokinase (MK),
glutathione reductase (GR), and glutaredoxin 2 (GRX2) are used for
the regeneration of ATP and NADP+.44,45 The pterin atoms of
H2F derived from glucose (red) and guanine (blue) are highlighted.
Details of each biosynthetic step are described in Figure S2.
Figure 3. Conversion of guanosine triphosphate (GTP) into
7,8-dihydroneopterin triphosphate (DHNTP) and monophosphate
(DHNMP). Shown are anion-exchange chromatography analyses of
GTP incubated for 2 h at 37 °C with (a) GTP cyclohydrolase I
(GTP-CH-I), which shows partial conversion to DHNTP, and (b) both
GTP-CH-I and 7,8-dihydroneopterin triphosphate pyrophosphohydro-
lase (DHNTPase), resulting in essentially complete conversion to
DHNMP. Production of guanosine diphosphate (GDP) is most likely
due to the nonenzymatic hydrolysis of GTP during incubation.
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disulﬁde (HED or oxidized β-mercaptoethanol) or cystine as
regenerating reagents and produces thiols as useful byproducts
that protect the enzymes and intermediates from oxidative
damage.
The conversion of GTP to DHNTP by GTP-CH-I marks the
entry point of the folate de novo pathway. It has been reported
that potassium and magnesium ions are positive allosteric
eﬀectors that can increase the rate of the GTP-CH-I reaction
up to 5-fold.46 The addition of these cations, however, was
insuﬃcient, as the reaction was found to be incomplete, giving a
poor yield of DHNTP (Figure 3a). In folate de novo
biosynthesis, dephosphorylation of DHNTP to 7,8-dihydro-
neopterin monophosphate (DHNMP) by DHNTP pyrophos-
phohydrolase (DHNTPase) is the biochemical step followed
by the GTP-CH-I reaction (Figure 2).47,48 Knockout of the
DHNTPase gene signiﬁcantly impairs folate metabolism in
E. coli,48 which suggests that DHNTP phosphohydrolysis is a
key regulatory step in folate metabolism. In other words, the
activity of GTP-CH-I is most likely inhibited by its own product,
DHNTP, which therefore needs to be immediately converted to
DHNMP in order to sustain the activity of GTP-CH-I. In the
presence of DHNTPase, GTP-CH-I showed a marked rate
enhancement (Figure S3), with nearly complete conversion of
GTP and a high yield of DHNMP (Figure 3b).
Additional enzymes are needed to convert DHNMP into
folate. To the best of our knowledge, the natural enzyme
responsible for the conversion of DHNMP to 7,8-dihydroneop-
terin (DHN) is unknown,37,48 and alkaline phosphatase (ALP)
was used instead as a surrogate. DHN is subjected to a retro-aldol
reaction catalyzed by dihydroneopterin aldolase (DHNA) to
yield 6-hydroxymethyl-7,8-dihydropterin (HMDP),49,50 which
then reacts with ATP in the presence of 6-hydroxymethyl
7,8-dihydropterin pyrophosphokinase (HPPK) (Figure 4).51
In E. coli, the resulting intermediate, 6-hydroxymethyl-7,8-
dihydropterin pyrophosphate (HMDPpp), is ﬁrst condensed
with pABA and then with glutamate, catalyzed by dihydropter-
oate synthase (DHPS)52 and dihydrofolate synthase (DHFS),53
respectively, to ﬁnally generate H2F. However, DHPS accepts
preassembled pABA-Glu as a substrate,54 so DHFS is not
required in the in vitro reaction. The entire H2F synthetic
pathway requires only one puriﬁcation step of the product, but
ALP needs to be removed by ultraﬁltration prior to the addition
of DHNA, HPPK, and DHPS because the phosphatase can also
catalyze the phosphorolysis of ATP and HMDPpp. Two addi-
tional modiﬁcations were made to further improve the overall
yield. A N2-ﬁlled glovebox system was used because all reduced
pterin-containing compounds, DHNTP, DHNMP, DHN,
HMDP, HMDPpp, and the ﬁnal product H2F, are oxygen-
sensitive.41 Also, cystine was found to be the preferred reagent
over HED for the NADP+ regeneration system operated by GR
andGRX2. Perhaps β-mercaptoethanol made from the reduction
of HED interferes with other enzymatic reactions, such as the
chelation of Zn2+ in GTP-CH-I. The total turnover numbers for
the regeneration of ATP from ADP by pyruvate kinase and
from AMP by pyruvate kinase/myokinase are both ∼100,55
while the total turnover number for our GR/GRX2-based
NADP+ recycling system can reach 5× 105.44 In general, a typical
biosynthetic cascade produced 6.6 mg of H2F from 9 mg of
glucose in an overall yield of 30%, i.e., the average yield of each
chemical transformation is in excess of 91%.
Synthesis of Selectively Labeled Folates. Five isotopi-
cally labeled H2Fs were synthesized using the newly developed in
vitro pathway (Figure 5a). Liquid chromatography−high-resolu-
tion mass spectrometry (LC-HRMS) analysis of [6-13C]H2F,
produced from [3-13C]D-glucose, showed an increase of ∼1
amu; 13C NMR spectroscopy revealed a singlet at 152 ppm.
Figure 4. Conversion of 7,8-dihydroneopterin (DHN) to dihydrofolate (H2F). Dihydroneopterin aldolase (DHNA) catalyzes the transformation of
DHN to 6-hydroxymethyl-7,8-dihydropterin (HMDP), which is pyrophosphorylated by 6-hydroxymethyl 7,8-dihydropterin pyrophosphokinase
(HPPK). The resulting 6-hydroxymethyl-7,8-dihydropterin pyrophosphate (HMDPpp) is converted to H2F by dihydropteroate synthase (DHPS),
whose promiscuity allows the use of preassembled pABA-Glu as the substrate and the omission of dihydrofolate synthase (DHFS) in the in vitro
synthetic pathway.
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Additionally, long-range coupling between 6-13C and protons on
C7 and C9 of [6-13C]H2F were observed in the
1H,13C HMBC
spectrum (Figure 5b).
To incorporate an 15N label into the pterin moiety at N5,
[7-15N]guanine was used. The resulting product showed∼1 amu
increase in LC-HRMS analysis and an 15N signal at 285 ppm
coupling to C7 and C9 protons in the 1H,15N HMBC spectrum
(Figure 5c).
When [3-13C]D-glucose and [7-15N]guanine were combined
to produce [5-15N][6-13C]H2F, a mass increase of ∼2 amu was
measured. The 13CNMR spectrum showed a doublet at 152 ppm
with a coupling constant 1JCN of 7.5 Hz; long-range coupling
between the protons on C7 and C9 was observed in the
1H,13C HMBC and 1H,15N HMBC spectra (see the Supporting
Information), indicating that both N5 and C6 of H2F were
isotopically enriched.
Similarly, [6,7,9-13C3]H2F and [5-
15N][6,7,9-13C3]H2F were
synthesized from 13C6-D-glucose and [7-
15N]guanine, and their
identities were conﬁrmed by HRMS and NMR spectroscopy
(see the Supporting Information).
Heavy-Atom Kinetic Isotope Eﬀects on the Reaction
Catalyzed by EcDHFR.The preparation of 13C- and 15N-labeled
Figure 5. H2Fs labeled with stable isotopes on the pterin ring system. (a) Patterns of isotopic distribution are determined by the starting material
isotopic enrichment used during H2F biosynthetic assembly. (b)
1H,13CHMBC and (c) 1H,15NHMBC spectra of [6-13C]H2F and [5-
15N]H2F. Protons
attached to C7 (3.95 ppm) and C9 (3.87 ppm) correlate to C6 (152 ppm) or N5 (285 ppm). 1H NMR spectra of all compounds and additional 2D
NMR characterization of [5-15N][6-13C]H2F, [6,7,9-
13C3]H2F and [5-
15N][6,7,9-13C3]H2F are reported in Figures S12−S15. HRMS data for all of the
compounds are given in Table S3 and Figures S16−S21. Isotopic enrichment was calculated to be at least 97% from the mass spectrometric data
(as illustrated in Figures S22−S24).
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dihydrofolates allowed the measurement of heavy-atom isotope
eﬀects for the reactions catalyzed by dihydrofolate reductase
(DHFR), a key enzyme in one-carbon metabolism and a vali-
dated target for the treatment of bacterial infections, malaria, and
cancer.56 DHFR catalyzes the reduction of H2F to H4F via
transfer of the pro-R hydride from C4 of NADPH to the Re face
on C6 accompanied by protonation of N5 of H2F (Figure 6).
57,58
Several aspects of the reaction mechanism warrant additional
investigation. In particular, the transition state structure and the
order of chemical transformation events have not been fully
determined.59,60 The active site of DHFR provides a favorable
environment for protonation of N5 by elevating the pKa from 2.6
to 6.5 and using an active-site water as the proton source.61,62
Solvent and hydrogen KIE measurements combined with site-
directed mutagenesis have suggested a stepwise mechanism in
which protonation precedes hydride transfer.63,64 However, D2O
increases the viscosity of the reaction buﬀer relative to H2O,
65,66
and site-directed modiﬁcation can alter the catalytic behavior
of an enzyme.67 Thus, additional mechanistic investigations
are needed to establish the order of events. Since isotopic
substitution does not alter the chemistry of the reaction but only
the kinetics, [6-13C]H2F and [5-
15N]H2F were used to measure
the 15N and 13C heavy-atom kinetic isotope eﬀects. Pre-steady-
state kinetic measurements at 15 °C by ﬂuorescence resonance
energy transfer from the active-site tryptophan in DHFR to the
reduced cofactor yield ﬁrst-order hydride transfer rate constants
with an accuracy of up to 0.7% (Figures S25−S27 and Table S4).
While a 13C KIE of 1.015 ± 0.006 was observed for the reduction
of [6-13C]H2F, the corresponding
15N KIE for [5-15N]H2F was
essentially unity (0.999 ± 0.006) under the same conditions.
To conﬁrm this ﬁnding, [5-15N][6-13C]H2F was used to probe
both positions at the same time, and the measured value for the
corresponding multiple heavy-atom KIE was 1.014 ± 0.008,
which is statistically identical to that obtained when the substrate
was labeled with 13C only.
The observed 15N KIE on hydride transfer indicates that
protonation of N5 is not isotopically sensitive, likely because
it is not rate-limiting under pre-steady-state conditions (as the
reaction is essentially irreversible,58 the observed KIE will tend to
unity rather than to the equilibrium isotope eﬀect).22 On the
other hand, the measured 13C KIE indicates that the hydride
transfer step is rate-determining. This strongly suggests a
stepwise mechanism. If the protonation and hydride transfer
steps were concerted, 15N- and 13C-labeled H2Fs should both
yield measurable KIEs;19,21,22 this interdependence may also lead
to an additive eﬀect in the multiple heavy-atom isotope eﬀect
measurement with the double-labeled substrate.19,21,22 In other
words, our results suggest that the pre-steady-state kinetic
measurement at pH 7.0 reveals only the step of hydride transfer
because protonation of N5 is in rapid equilibrium and the
ensemble of reaction-ready conformations is mostly populated
with protonated H2F. Importantly, these results conﬁrm the
validity of previous solvent KIE and site-directed mutagenesis
studies, which also concluded that the sequence of chemical
events (protonation and hydride transfer) is distinct and strictly
ordered.64,68 Overall, the results provided here strongly support
a mechanism where protonation and hydride transfer are
independent of each other and occur in a stepwise fashion.
■ CONCLUSIONS
Dihydrofolate was produced enzymatically in an easy one-pot,
high-yielding reaction sequence from glucose, guanine, and
pABA-Glu that required only a single puriﬁcation step. Potential
problems with individual steps during the synthesis could be
overcome through the use of a one-pot reaction. This metho-
dology can be used to generate dihydrofolates labeled in speciﬁc
positions with stable isotopes with average overall yields of
>30%, facilitating many applications in cell biology and
mechanistic enzymology.27−29,61,69,70 For the ﬁrst time, heavy-
atom KIEs for the DHFR-catalyzed reduction of H2F could be
measured to provide strong support for a stepwise reduction of
the substrate in which protonation at N5 and hydride transfer
from C4 of the NADPH to C6 of protonated dihydrofolate
proceed independently. This chemoenzymatic pterin synthesis
can be integrated into other enzymatic procedures to generate
folate derivatives31,32 and other high-value natural products that
are not easily accessible by conventional synthesis.71 It can be
applied to nutritional, medical, and cell-biological research to
address questions of in vivo bioavailability and to explore the
kinetics of folate metabolism in intact cells and organisms.70,72−76
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(17) Sköld, O. Sulfonamides and Trimethorpim. In Antimicrobial Drug
Resistance; Mayers, D. L., Ed.; Humana Press: New York, 2009; Vol. 1,
pp 259−269.
(18) Copeland, R. A.; Harpel, M. R.; Tummino, P. J. Expert Opin. Ther.
Targets 2007, 11, 967−978.
(19) Cleland, W. W. Arch. Biochem. Biophys. 2005, 433, 2−12.
(20) Vardi-Kilshtain, A.; Nitoker, N.; Major, D. T. Arch. Biochem.
Biophys. 2015, 582, 18−27.
(21) Cook, P. F. Isot. Environ. Health Stud. 1998, 34, 3−17.
(22) O’Leary, M. H. Annu. Rev. Biochem. 1989, 58, 377−401.
(23) Wharton, C. W. Nat. Prod. Rep. 2000, 17, 447−453.
(24) Palmer, A. G. Acc. Chem. Res. 2015, 48, 457−65.
(25) Schramm, V. L. Acc. Chem. Res. 2015, 48, 1032−1039.
(26) Maunder, P.; Finglas, P.; Mallet, A.; Mellon, F.; Razzaque, M.;
Ridge, B.; Vahteristo, L.; Witthoft, C. J. Chem. Soc., Perkin Trans. 1 1999,
1311−1323.
(27) Cocco, L.; Groff, J. P.; Temple, C.; Montgomery, J. A.; London, R.
E.; Matwiyoff, N. A.; Blakley, R. L. Biochemistry 1981, 20, 3972−3978.
(28) Selinsky, B. S.; Perlman, M. E.; London, R. E.; Unkefer, C. J.;
Mitchell, J.; Blakley, R. L. Biochemistry 1990, 29, 1290−1296.
(29) Cheung, H. T. A.; Birdsall, B.; Frenkiel, T. A.; Chau, D. D.;
Feeney, J. Biochemistry 1993, 32, 6846−6854.
(30) Cowart, M.; Falzone, C. J.; Benkovic, S. J. J. Labelled Compd.
Radiopharm. 1994, 34, 67−71.
(31) Saeed, M.; Tewson, T. J.; Erdahl, C. E.; Kohen, A.Nucl. Med. Biol.
2012, 39, 697−701.
(32) Curthoys, N. P.; Scott, J. M.; Rabinowitz, J. C. J. Biol. Chem. 1972,
247, 1959−1964.
(33) Moran, R. G.; Keyomarsi, K.; Colman, P. D. Methods Enzymol.
1986, 122, 309−312.
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